Biopharma Competition Pharma Physicians 
PM360
APRIL 22, 2024
From important changes to engaging physicians to finding out how new technologies will help address HCPs education needs, hear what our specialist had to say. What do you think are the most important changes to engaging physicians our industry needs to keep in mind now?
Clarivate
JULY 5, 2023
The Biosimilars Forum has hailed 2022 as a watershed year that could create a more competitive U.S. Clarivate research indicates biosimilar competition will drive down prices and relative market share of HUMIRA ® in the U.S. By end of year, as many as ten adalimumab biosimilars could be on the U.S. from 91% in 2023 to 36% by 2031.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Clarivate
APRIL 24, 2023
CVS then began affiliating with health systems across the country (like Cleveland Clinic ) for physician oversight of MinuteClinic’s staffed midlevel providers, just as Walgreens was rising as a formidable competitor in the convenient care space through its own walk-in clinics that it launched in fall 2006. Key acquisitions by U.S.
Clarivate
OCTOBER 25, 2023
Unlike in Part D, Part B drugs are physician administered and there is less certainty regarding which drugs will be tapped for negotiations (i.e., exclusions exist for orphan drug designation and biosimilar competition ). Nonetheless, Clarivate expects the initial list to include oncology treatments KEYTRUDA® and OPDIVO®.
Clarivate
APRIL 18, 2024
Humana is following a similar growth strategy as it sharpens competition with UnitedHealthcare in the Medicare Advantage sector. Signify’s healthcare platform also assists 65,000 provider partners to participate in value-based care with nearly 1 million attributed lives Oak Street Health acquisition May 2023 CVS acquired Oak Street for $10.6
Clarivate
OCTOBER 10, 2022
Fruquintinib will face fierce competition should it be approved in the third- and later-line setting. The question of which KRAS inhibitor is most effective remains elusive, although being first to market in addition to strong efficacy and safety data could differentiate the more competitive agent. Key ESMO findings. months vs. 20.3
Clarivate
MARCH 12, 2024
For the approximately 10% of biopharma candidates that actually manage to make it to clinical trials, many fail to achieve enough revenue once they reach the market to justify the R&D effort. In fact, one-third of drugs launched over a recent 10-year period fell short of sales expectations.
Expert insights. Personalized for you.
59 
Let's personalize your content